Respiratory Virus News and Research

RSS

Individualized vent-splitter may allow multiple COVID-19 patients to share single ventilator

As the pandemic swept across the nation in March, so did urgent questions about the virus' potential strain on the healthcare system.

22 Apr 2020

How does COVID-19 attack the body?

The coronavirus disease (COVID-19) attacks the lungs, leading to pneumonia, and eventually, a cascade of serious complications. But how does COVID-19 kill? Is it the virus itself or the result of the person’s immune system response?

13 Apr 2020

American Lung Association launches a $25M initiative to end COVID-19

As the nation’s leading voluntary lung health organization, the American Lung Association is launching a $25M initiative to end COVID-19 and defend against future respiratory virus pandemics.

10 Apr 2020

McMaster: Common medical masks are good for most COVID-19 treatment

The N95 respirator masks should be preserved for health-care workers involved in inserting breathing tubes for patients with COVID-19. More common medical masks are fine for all other COVID-19 treatment, says preliminary research from McMaster University.

6 Apr 2020

INTEGRA, BioTools and Sullivan Nicolaides Pathology work together to accelerate COVID-19 testing

The global COVID-19 pandemic has placed unprecedented demands on pathology services to test patient samples for the novel SARS-CoV-2 coronavirus alongside their pre-existing respiratory virus panels.

From INTEGRA Biosciences 31 Mar 2020

New modeling study estimates impact of physical distancing in reducing SARS-CoV-2 spread

A new modeling study conducted in a simulated Singapore setting has estimated that a combined approach of physical distancing interventions, comprising quarantine (for infected individuals and their families), school closure, and workplace distancing, is most effective at reducing the number of SARS-CoV-2 cases compared with other intervention scenarios included in the study.

25 Mar 2020

CEL-SCI collaborates with UGA Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy

CEL-SCI Corporation announced today it has signed a collaboration agreement with the University of Georgia’s Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy.

23 Mar 2020

As coronavirus spreads widely, millions of older Americans live in counties with no ICU beds

More than half the counties in America have no intensive care beds, posing a particular danger for more than 7 million people who are age 60 and up - older patients who face the highest risk of serious illness or death from the rapid spread of COVID-19, a Kaiser Health News data analysis shows.

20 Mar 2020

What does COVID-19 do to the body?

The novel coronavirus SARS-CoV-2, also known as 2019-nCoV, is the virus that causes COVID-19, and that is spreading throughout the world is causing panic in almost all countries. With a death rate ranging from 1% to 2% in young patients but about 5%-8% in elderly and sick patients, it is capable of ravaging multiple organ systems in the human body.

12 Mar 2020

Measles re-emerging globally

Measles is a common childhood illness but can cause more than a passing fever with rash. It could turn out to be a complicated and severe illness, warn doctors in a new paper published in February 2020 in the journal BMJ Case Reports.

17 Feb 2020

Coronavirus tests public health infrastructure in the heartland

Every weekday at noon since Jan. 27, the Missouri Department of Health and Senior Services Director Randall Williams gathers his outbreak response team for a meeting on coronavirus.

13 Feb 2020

To fight Chinese outbreak, doctors deploy drugs targeting HIV, malaria and Ebola

As the scientific community scrambles to find a drug that can effectively treat tens of thousands of patients sickened by a new respiratory virus, they are trying some surprising remedies: medicines targeting known killers like HIV, Ebola and malaria.

13 Feb 2020

PolyU develops fully automated, rapid diagnostic platform for detecting respiratory infectious diseases

The Hong Kong Polytechnic University today announced the development of the world's most comprehensive automated multiplex diagnostic system (the System) which includes a fully automated machine and a multiplex full-screening panel for the point-of-care genetic testing of respiratory infectious disease including the 2019-nCoV.

11 Feb 2020

SUNY Downstate epidemiologist is part of international initiative to uncover clues on coronavirus

Twice each day, SUNY Downstate School of Public Health evolutionary epidemiologist Sergios-Orestis Kolokotronis, PhD, joins a global group of scientists in reviewing a worldwide database of the latest genomic information about the Wuhan strain of novel coronavirus (2019-nCoV) that so far has infected more than 28,000 people, including more than 250 outside of China, and resulted in at least 560 deaths.

6 Feb 2020

Key insights on how to prevent novel coronavirus

The 2019 Novel Coronavirus (2019-nCoV) is a new respiratory virus that was first identified in Wuhan, China.

27 Jan 2020

Bacteria in babies' noses could offer clues to recovery from first cough or cold

New research on the types of bacteria living in babies' noses could offer clues as to why some recover quickly from their first cough or cold, while others suffer for longer.

3 Dec 2018

Phase 2 study of ziresovir for treating hospitalized RSV infected infants achieves significant progress

Ark Biosciences, a biotech company developing proprietary therapeutics for viral infection and respiratory diseases, announced today the significant progress in its phase 2 proof-of-concept study of ziresovir in the treatment of hospitalized RSV infected infants.

1 Nov 2018

Airport security trays carry more microbes than toilet seats

A team of researchers from Finland and Britain have shown that over half of all the trays or security bins that the airport authorities use at the security clearance areas carry viruses that can cause respiratory infections.

6 Sep 2018

Pfizer starts Phase 1/2 study of RSV vaccine candidate in healthy adult volunteers

Pfizer Inc. today announced that it has started a Phase 1/2 trial of its respiratory syncytial virus (RSV) vaccine candidate in healthy adult volunteers. RSV is a common respiratory virus that affects the lungs and airways, with significant impact on young children and older adults.

22 May 2018

SpeeDx signs distribution agreement with Serosep to strengthen sales in the UK and Ireland

SpeeDx has announced a distribution agreement with Serosep Ltd, a leading manufacturer and distributor of laboratory diagnostic solutions. This will strengthen sales channels in the UK and Ireland, ensuring greater access to SpeeDx’s multiplexed PlexPCR and ResistancePlus molecular diagnostic tests across the region.

24 Apr 2018